Man of Many on MSN
From Ozempic to BPC-157: Are peptides safe, legal, and worth it?
Peptides are one of the biggest topics in health & fitness right now. Whether the science backs it up depends on which one ...
Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi (R) for the treatment of adults with polycythemia vera (PV). The Company is seeking a ropeginterferon alfa-2b-njft label ...
An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...
Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.
Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to treat the rare condition Fabry disease. In the phase 1/2 study, two ...
In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
In this video, Melissa Shoemaker, MD, MPH, compares oral GLP-1 medication to previous anti-obesity treatments.
MIAMI - MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) has begun dosing the final cohort in its Phase 1 multiple ascending dose clinical trial for Ketamir-2, an oral NMDA receptor antagonist targeting ...
Ozempic is prescribed for adults with type 2 diabetes. It’s given as an injection under the skin once per week. The recommended starting dose of Ozempic is 0.25 milligrams (mg) injected once per week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results